全文获取类型
收费全文 | 152613篇 |
免费 | 12348篇 |
国内免费 | 332篇 |
专业分类
耳鼻咽喉 | 1390篇 |
儿科学 | 4519篇 |
妇产科学 | 3382篇 |
基础医学 | 23603篇 |
口腔科学 | 3760篇 |
临床医学 | 14511篇 |
内科学 | 31046篇 |
皮肤病学 | 2814篇 |
神经病学 | 14909篇 |
特种医学 | 6081篇 |
外国民族医学 | 20篇 |
外科学 | 18436篇 |
综合类 | 760篇 |
现状与发展 | 1篇 |
一般理论 | 113篇 |
预防医学 | 17017篇 |
眼科学 | 2314篇 |
药学 | 9397篇 |
中国医学 | 261篇 |
肿瘤学 | 10959篇 |
出版年
2023年 | 743篇 |
2022年 | 565篇 |
2021年 | 2513篇 |
2020年 | 2056篇 |
2019年 | 3031篇 |
2018年 | 3686篇 |
2017年 | 3057篇 |
2016年 | 3282篇 |
2015年 | 3652篇 |
2014年 | 4835篇 |
2013年 | 6416篇 |
2012年 | 9480篇 |
2011年 | 9430篇 |
2010年 | 5104篇 |
2009年 | 5240篇 |
2008年 | 8332篇 |
2007年 | 8504篇 |
2006年 | 8162篇 |
2005年 | 7712篇 |
2004年 | 6671篇 |
2003年 | 6273篇 |
2002年 | 5708篇 |
2001年 | 4766篇 |
2000年 | 4738篇 |
1999年 | 4222篇 |
1998年 | 1768篇 |
1997年 | 1442篇 |
1996年 | 1486篇 |
1995年 | 1372篇 |
1994年 | 1262篇 |
1993年 | 1141篇 |
1992年 | 2866篇 |
1991年 | 2604篇 |
1990年 | 2495篇 |
1989年 | 2332篇 |
1988年 | 2126篇 |
1987年 | 1871篇 |
1986年 | 1801篇 |
1985年 | 1710篇 |
1984年 | 1233篇 |
1983年 | 1069篇 |
1982年 | 626篇 |
1981年 | 554篇 |
1980年 | 457篇 |
1979年 | 915篇 |
1978年 | 571篇 |
1977年 | 490篇 |
1974年 | 482篇 |
1973年 | 456篇 |
1972年 | 407篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Narges K Tafreshi David L Morse Marie Catherine Lee 《World journal of clinical oncology》2020,11(4):169-179
Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2 protein. In comparison to other types of breast cancer, TNBC characterizes for its aggressive behavior, more prone to early recurrence and a disease with poor response to molecular target therapy. Although TNBC is identified in only 25%-30% of American breast cancer cases annually, these tumors continue to be a therapeutic challenge for clinicians for several reasons: Tumor heterogeneity, limited and toxic systemic therapy options, and often resistance to current standard therapy, characterized by progressive disease on treatment, residual tumor after cytotoxic chemotherapy, and early recurrence after complete surgical excision. Cell-surface targeted therapies have been successful for breast cancer in general, however there are currently no approved cell-surface targeted therapies specifically indicated for TNBC. Recently, several cell-surface targets have been identified as candidates for treatment of TNBC and associated targeted therapies are in development. The purpose of this work is to review the current clinical challenges posed by TNBC, the therapeutic approaches currently in use, and provide an overview of developing cell surface targeting approaches to improve outcomes for treatment resistant TNBC. 相似文献
102.
103.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
104.
105.
106.
107.
108.
109.
110.
Overbeek Kasper A. Cahen Djuna L. Kamps Anne Konings Ingrid C. A. W. Harinck Femme Kuenen Marianne A. Koerkamp Bas Groot Besselink Marc G. van Eijck Casper H. Wagner Anja Ausems Margreet G. E. van der Vlugt Manon Fockens Paul Vleggaar Frank P. Poley Jan-Werner van Hooft Jeanin E. Bleiker Eveline M. A. Bruno Marco J. 《Familial cancer》2020,19(3):247-258
Familial Cancer - In high-risk individuals participating in a pancreatic cancer surveillance program, worrisome features warrant for intensified surveillance or, occasionally, surgery. Our... 相似文献